Zurich Cantonal Bank
KROS icon

Zurich Cantonal Bank’s Keros Therapeutics KROS Stock Holding History

Zurich Cantonal Bank’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1K Buy
1,415
+716
+102% +$7.98K ﹤0.01% 2484
2026
Q1 		$7.72K Buy
+699
New +$10.8K ﹤0.01% 2491
2025
Q1 		– Sell
-7,449
Closed -$118K – 2660
2024
Q4 		$118K Buy
7,449
+2,078
+39% +$108K ﹤0.01% 2377
2024
Q3 		$312K Buy
5,371
+1,994
+59% +$98.5K ﹤0.01% 1854
2024
Q2 		$154K Sell
3,377
-1
-0% -$54 ﹤0.01% 2168
2024
Q1 		$224K Buy
3,378
+301
+10% +$17.8K ﹤0.01% 1996
2023
Q4 		$122K Sell
3,077
-37
-1% -$1.16K ﹤0.01% 2350
2023
Q3 		$99.3K Sell
3,114
-106
-3% -$3.96K ﹤0.01% 2354
2023
Q2 		$129K Buy
3,220
+2,691
+509% +$118K ﹤0.01% 2205
2023
Q1 		$22.6K Buy
529
+118
+29% +$5.96K ﹤0.01% 2731
2022
Q4 		$19.7K Sell
411
-79
-16% -$3.69K ﹤0.01% 2757
2022
Q3 		$18K Hold
490
– – ﹤0.01% 2815
2022
Q2 		$14K Sell
490
-40
-8% -$1.75K ﹤0.01% 2830
2022
Q1 		$29K Sell
530
-254
-32% -$13K ﹤0.01% 2615
2021
Q4 		$46K Sell
784
-42
-5% -$2.09K ﹤0.01% 2768
2021
Q3 		$33K Sell
826
-11
-1% -$391 ﹤0.01% 2722
2021
Q2 		$36K Buy
837
+27
+3% +$1.46K ﹤0.01% 2517
2021
Q1 		$50K Buy
+810
New +$51.3K ﹤0.01% 2387

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Zurich Cantonal Bank's KROS Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Keros Therapeutics (KROS) stake by 102% in Q2 2026, buying an estimated $7.98K and bringing the position to 1,415 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2484.

Zurich Cantonal Bank first reported a position in KROS in Q1 2021 and has held it in 18 quarters since. The position peaked at $312K in Q3 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Zurich Cantonal Bank held 1,415 shares of Keros Therapeutics worth $15.1K as of Q2 2026.
  • Zurich Cantonal Bank bought 716 Keros Therapeutics shares in Q2 2026, an estimated $7.98K.
  • Keros Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2484 holding.
  • Zurich Cantonal Bank first reported a position in Keros Therapeutics in Q1 2021 and has held it in 18 quarters since.
  • Zurich Cantonal Bank's Keros Therapeutics position peaked at $312K in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.